NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
07/21/2026
Back to search
Official data from USPTO
NEUROCYTONIX
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: US
Quick snapshot
NEUROCYTONIX
ST13
US500000097016422Class
10, 44
Filing
97016422
Registration
8355826
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
50
Latest update
07/21/2026
Classification
Registered
Trademark type
Word
Nice classes
10, 44
Filing date
09/08/2021
Registration date
07/21/2026
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
07/21/2026
Last transaction
07/21/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
2019-12-00
First use in commerce
10/06/2025
Drawing code
4
Owner type
03
Owner location
Rockville, MD, US
Examiner
KLUWE, CHERYL D
Law office
N80
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
NeuroCytonix, Inc.
Representatives
Jennifer C. Debrow Taft Stettinius & Hollister LLP
Technical classification
Nice Classes
Class 10Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 10
Neural tissue engineering apparatus for medical use of instantaneous magnetic fields and low spectrum radio frequency waves for neurological therapeutic purposes; Magnetic resonance imaging (MRI) apparatus for medical purposes to target nervous system lesions and modulate a signal to stimulate cell growth and cell repair in human nervous system for treatment of non-progressive and progressive brain diseasesconditions of the central and peripheral nervous systemneurological and psychiatric disordersspinal cord injuries
Class 44
Medical treatment of non-progressive and progressive brain diseasesconditions of the central and peripheral nervous systemneurological and psychiatric disordersspinal cord injuriesusing magnetic resonance modulationradio frequency cell signaling technologyrotational field quantum magnetic resonance
Publications
History of USPTO decisions and trademark events.
50 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
07/21/2026
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
07/02/2026
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
07/02/2026
SUPC
STATEMENT OF USE PROCESSING COMPLETE
06/16/2026
IUAF
USE AMENDMENT FILED
03/12/2026
EISU
TEAS STATEMENT OF USE RECEIVED
03/12/2026
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
11/13/2025
EX5G
SOU EXTENSION 5 GRANTED
11/12/2025
EXT5
SOU EXTENSION 5 FILED
08/11/2025
EEXT
SOU TEAS EXTENSION RECEIVED
08/11/2025
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
03/02/2025
EX4G
SOU EXTENSION 4 GRANTED
03/01/2025
EXT4
SOU EXTENSION 4 FILED
02/28/2025
EEXT
SOU TEAS EXTENSION RECEIVED
02/28/2025
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
09/26/2024
EX3G
SOU EXTENSION 3 GRANTED
09/26/2024
EXT3
SOU EXTENSION 3 FILED
09/26/2024
EEXT
SOU TEAS EXTENSION RECEIVED
09/26/2024
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
02/28/2024
EX2G
SOU EXTENSION 2 GRANTED
02/27/2024
EXT2
SOU EXTENSION 2 FILED
02/27/2024
EEXT
SOU TEAS EXTENSION RECEIVED
02/27/2024
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
06/10/2023
EX1G
SOU EXTENSION 1 GRANTED
06/08/2023
EXT1
SOU EXTENSION 1 FILED
06/08/2023
EEXT
SOU TEAS EXTENSION RECEIVED
06/08/2023
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
05/16/2023
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
05/16/2023
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
05/16/2023
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
04/25/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
02/28/2023
PUBO
PUBLISHED FOR OPPOSITION
02/28/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
02/08/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
01/24/2023
XAEC
EXAMINER'S AMENDMENT ENTERED
01/24/2023
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
01/24/2023
GNEA
EXAMINERS AMENDMENT E-MAILED
01/24/2023
CNEA
EXAMINERS AMENDMENT -WRITTEN
01/24/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
11/15/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
11/14/2022
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
11/14/2022
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
06/13/2022
GNRT
NON-FINAL ACTION E-MAILED
06/13/2022
CNRT
NON-FINAL ACTION WRITTEN
06/13/2022
DOCK
ASSIGNED TO EXAMINER
06/13/2022
TAEA
TEAS AMENDMENT ENTERED BEFORE ATTORNEY ASSIGNED
10/21/2021
PARI
TEAS VOLUNTARY AMENDMENT RECEIVED
10/21/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
10/18/2021
NWAP
NEW APPLICATION ENTERED
09/11/2021
Continuous trademark protection
Get notified about every new filing that threatens NEUROCYTONIX or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.